Incyte's HIV Drug Shows Promise
July 26, 2005
Incyte Corp.'s drug Reverset showed promise in reducing HIV in patients whose current regimens are not working, according to data the company presented at the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment in Rio de Janeiro.
In a six-month trial involving 199 U.S. and European patients, the greatest viral suppression in highly treatment-experienced patients was seen at the once-daily 200-mg Reverset dose. The once-daily 50-mg and 100-mg dose levels were less effective. At least two cases of pancreatitis were found in patients taking the 200-mg dose in combination with didanosine and tenofovir, but Incyte officials said didanosine has been historically associated with a risk of pancreatitis.
"At the 200-milligram dose, which is the highest dose tested in the study and the dose we plan to carry forward into Phase III [testing], the drug appears to have been very well tolerated and to have substantial and significant antiviral potency," said CEO Paul Friedman.
Wall Street Journal
07.26.05; Peter Loftus
This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.